5-HT5A receptor

5-Hydroxytryptamine (serotonin) receptor 5A, also known as HTR5A, is a protein that in humans is encoded by the HTR5A gene.[5][6] Agonists and antagonists for 5-HT receptors, as well as serotonin uptake inhibitors, present promnesic (memory-promoting) and/or anti-amnesic effects under different conditions, and 5-HT receptors are also associated with neural changes.

HTR5A
Identifiers
AliasesHTR5A, 5-HT5A, 5-HT5A receptor, 5-hydroxytryptamine receptor 5A
External IDsOMIM: 601305 MGI: 96283 HomoloGene: 22461 GeneCards: HTR5A
Gene location (Human)
Chr.Chromosome 7 (human)[1]
Band7q36.2Start155,070,324 bp[1]
End155,087,392 bp[1]
RNA expression pattern
More reference expression data
Orthologs
SpeciesHumanMouse
Entrez

3361

15563

Ensembl

ENSG00000157219

ENSMUSG00000039106

UniProt

P47898

P30966

RefSeq (mRNA)

NM_024012

NM_008314

RefSeq (protein)

NP_076917

NP_032340

Location (UCSC)Chr 7: 155.07 – 155.09 MbChr 5: 27.84 – 27.86 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Function

The gene described in this record is a member of 5-hydroxytryptamine receptor family and encodes a multi-pass membrane protein that functions as a receptor for 5-hydroxytryptamine and couples to G proteins, negatively influencing cAMP levels via Gi and Go.[7] This protein has been shown to function in part through the regulation of intracellular Ca2+ mobilization.[5] The 5-HT5A receptor has been shown to be functional in a native expression system.[8]

Rodents have been shown to possess two functional 5-HT5 receptor subtypes, 5-HT5A and 5-HT5B,[9] however while humans possess a gene coding for the 5-HT5B subtype, its coding sequence is interrupted by stop codons, making the gene non-functional, and so only the 5-HT5A subtype is expressed in human brain.[10]

It also appears to serve as a presynaptic serotonin autoreceptor.[11]

Clinical significance

The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) has been implicated in a wide range of psychiatric conditions and also has vasoconstrictive and vasodilatory effects.[5]

Selective Ligands

Few highly selective ligands are commercially available for the 5-HT5A receptor. When selective activation of this receptor is desired in scientific research, the non-selective serotonin receptor agonist 5-Carboxamidotryptamine can be used in conjunction with selective antagonists for its other targets (principally 5-HT1A, 5-HT1B, 5-HT1D, and 5-HT7). Research in this area is ongoing.[12][13]

Agonists

Antagonists

See also

References
  1. GRCh38: Ensembl release 89: ENSG00000157219 - Ensembl, May 2017
  2. GRCm38: Ensembl release 89: ENSMUSG00000039106 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. "Entrez Gene: HTR5A 5-hydroxytryptamine (serotonin) receptor 5A".
  6. Rees S, den Daas I, Foord S, Goodson S, Bull D, Kilpatrick G, Lee M (Dec 1994). "Cloning and characterisation of the human 5-HT5A serotonin receptor". FEBS Letters. 355 (3): 242–6. doi:10.1016/0014-5793(94)01209-1. PMID 7988681. S2CID 36425845.
  7. Francken BJ, Jurzak M, Vanhauwe JF, Luyten WH, Leysen JE (Nov 1998). "The human 5-ht5A receptor couples to Gi/Go proteins and inhibits adenylate cyclase in HEK 293 cells". European Journal of Pharmacology. 361 (2–3): 299–309. doi:10.1016/S0014-2999(98)00744-4. PMID 9865521.
  8. Goodfellow NM, Bailey CD, Lambe EK (Apr 2012). "The native serotonin 5-HT(5A) receptor: electrophysiological characterization in rodent cortex and 5-HT(1A)-mediated compensatory plasticity in the knock-out mouse". The Journal of Neuroscience. 32 (17): 5804–9. doi:10.1523/JNEUROSCI.4849-11.2012. PMC 4644074. PMID 22539842.
  9. Matthes H, Boschert U, Amlaiky N, Grailhe R, Plassat JL, Muscatelli F, Mattei MG, Hen R (Mar 1993). "Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization". Molecular Pharmacology. 43 (3): 313–9. PMID 8450829.
  10. Nelson DL (Feb 2004). "5-HT5 receptors". Current Drug Targets. CNS and Neurological Disorders. 3 (1): 53–8. doi:10.2174/1568007043482606. PMID 14965244.
  11. {{cite journal | vauthors = Thomas DR, Soffin EM, Roberts C, Kew JN, de la Flor RM, Dawson LA, Fry VA, Coggon SA, Faedo S, Hayes PD, Corbett DF, Davies CH, Hagan JJ | title = SB-699551-A (3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[(4'-{[(2-phenylethyl)amino]methyl}-4-biphenylyl)methyl]propanamide dihydrochloride), a novel 5-ht5A receptor-selective antagonist, enhances 5-HT neuronal function: Evidence for an autoreceptor role for the 5-ht5A receptor in guinea pig brain | journal = Neuropharmacology | volume = 51 | issue = 3 | pages = 566–77 | date = Sep 2006 | pmid = 16846620 | doi = 10.1016/j.neuropharm.2006.04.019 | s2cid = 543423 }}
  12. Wesołowska A (2002). "In the search for selective ligands of 5-HT5, 5-HT6 and 5-HT7 serotonin receptors" (PDF). Polish Journal of Pharmacology. 54 (4): 327–41. PMID 12523486.
  13. Peters JU, Lübbers T, Alanine A, Kolczewski S, Blasco F, Steward L (Jan 2008). "Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: optimising brain penetration". Bioorganic & Medicinal Chemistry Letters. 18 (1): 262–6. doi:10.1016/j.bmcl.2007.10.078. PMID 18023344.
  14. The RBI Handbook of Receptor Classification and Signal Transduction, page 114 (1995)ISBN 0-9640548-1-7
  15. Dietz BM, Mahady GB, Pauli GF, Farnsworth NR (Aug 2005). "Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro". Brain Research. Molecular Brain Research. 138 (2): 191–7. doi:10.1016/j.molbrainres.2005.04.009. PMC 5805132. PMID 15921820.
  16. Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
  17. US 6750221, "Use of 5-HT5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances", published 2004-06-15
  18. Yamazaki M, Okabe M, Yamamoto N, Yarimizu J, Harada K (2015). "Novel 5-HT5A receptor antagonists ameliorate scopolamine-induced working memory deficit in mice and reference memory impairment in aged rats". J. Pharmacol. Sci. 127 (3): 362–9. doi:10.1016/j.jphs.2015.02.006. PMID 25837935.
  19. Yamazaki M, Harada K, Yamamoto N, Yarimizu J, Okabe M, Shimada T, Ni K, Matsuoka N (2014). "ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia". Eur Neuropsychopharmacol. 24 (10): 1698–708. doi:10.1016/j.euroneuro.2014.07.009. PMID 25108314.
  20. Wu J, Li Q, Bezprozvanny I (2008). "Evaluation of Dimebon in cellular model of Huntington's disease". Molecular Neurodegeneration. 3 (1): 15. doi:10.1186/1750-1326-3-15. PMC 2577671. PMID 18939977.

Further reading
  • "5-ht5a". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.
  • Human HTR5A genome location and HTR5A gene details page in the UCSC Genome Browser.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.